Investor News

Rainbow Crops raises €9.7M seed round to scale AI-driven multiplex gene editing for next-generation crops

Rainbow Crops raises €9.7M seed round to scale AI-driven multiplex gene editing for next-generation crops

The round was led by Italian venture capital company LIFTT, together with its vehicle LIFTT EuroInvest

European Life Sciences Coalition launched to strengthen Europe’s life sciences investment ecosystem

European Life Sciences Coalition launched to strengthen Europe’s life sciences investment ecosystem

Confo Therapeutics – Unlocking the power of GPCRs

Confo Therapeutics – Unlocking the power of GPCRs

MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-based Biotherapeutic Product Pipeline

MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-based Biotherapeutic Product Pipeline

Spica Therapeutics Secures €1 Million VLAIO Grant to Advance Groundbreaking Macrophage-Targeted Cancer Therapy

Spica Therapeutics Secures €1 Million VLAIO Grant to Advance Groundbreaking Macrophage-Targeted Cancer Therapy

Animab Secures EUR 10 Million in Series B Financing to Launch Nanoprotec® in Europe and Expand Pipeline

Animab Secures EUR 10 Million in Series B Financing to Launch Nanoprotec® in Europe and Expand Pipeline

Animab Secures EUR 10 Million in Series B Financing to Launch Nanoprotec® in Europe and Expand Pipeline

Animab Secures EUR 10 Million in Series B Financing to Launch Nanoprotec® in Europe and Expand Pipeline

Spica Therapeutics Closes €10 Million Seed Round to Advance Macrophage-Targeted Therapies

Spica Therapeutics Closes €10 Million Seed Round to Advance Macrophage-Targeted Therapies

Spica Therapeutics Closes €10 Million Seed Round to Advance Macrophage-Targeted Therapies

Spica Therapeutics Closes €10 Million Seed Round to Advance Macrophage-Targeted Therapies

Lever Bio Announces a €4 Million Financing Round and a Strategic Partnership with VIB to Advance Four Novel Immuno-Oncology Assets

Lever Bio Announces a €4 Million Financing Round and a Strategic Partnership with VIB to Advance Four Novel Immuno-Oncology Assets

Lever Bio Announces a €4 Million Financing Round and a Strategic Partnership with VIB to Advance Four Novel Immuno-Oncology Assets

Lever Bio Announces a €4 Million Financing Round and a Strategic Partnership with VIB to Advance Four Novel Immuno-Oncology Assets

Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer

Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be